CB-010

DB17711InvestigationalCell transplant therapies

CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19. It is being investigated for the treatment of follicular lymphoma.

Mechanism: Pharmacologically active on B-lymphocyte antigen CD19
Curator reviewed
Code names: CB-010

Resolves to

Compound

Targets

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with CB-010, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.